Opendata, web and dolomites

STOP-COPD SIGNED

PulseHaler™: A Novel Treatment Device for COPD.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STOP-COPD project word cloud

Explore the words cloud of the STOP-COPD project. It provides you a very rough idea of what is the project "STOP-COPD" about.

grant    commercial    finalized    160    certificate    demonstrated    reimbursement    quality    smei    substantially    markets    brea    approval    small    combined    incorporating    functional    burden    employees    chronic    leadership    shown    gather    manufacturing    magnitude    kols    team    seasoned    kills    debilitating    annually    finalize    treat    predictor    actions    receiving    obstructive    medical    business    device    trial    continue    50m    data    sites    treatment    mortality    opening    capacity    seal    morbidity    trade    copd    sme    obtain    progressive    usability    invented    sufferers    efficacy    complete    reduce    excellence    exercise    successful    arrangements    market    strongest    additional    ltd    winning    patient    initial    difficult    strategy    prepare    thereby    clinical    airways    functions    respinova    life    21b    collapse    141b    regulatory    annual    lungs    launch    israel    europeans    pulsehaler    decades    revolutionary    intend    disease    first    pulmonary    patients   

Project "STOP-COPD" data sheet

The following table provides information about the project.

Coordinator
RESPINOVA LTD 

Organization address
address: 8 HACHOSHLIM ST.
city: HERZLIYA PITUACH
postcode: 4672408
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://www.respinova.com
 Total cost 3˙449˙093 €
 EC max contribution 2˙414˙365 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RESPINOVA LTD IL (HERZLIYA PITUACH) coordinator 2˙414˙365.00

Map

 Project objective

Chronic Obstructive Pulmonary Disease (COPD) is a progressive, debilitating, disease of the lungs which affects 50M Europeans and kills 160,000 every year, with an annual cost burden of €141B. Respinova Ltd. has invented a novel device, called PulseHaler™, to treat COPD in a revolutionary way by opening the small airways, which are known to collapse in COPD patients thereby making it increasingly difficult to breathe. No other COPD treatment in the market today can effectively open the small airways. In a clinical trial, the PulseHaler™ was shown to substantially improve the functional capabilities and quality of life of COPD sufferers. If PulseHaler™ can reduce costs by the same magnitude to which it has been demonstrated to improve patient’s exercise capacity (the strongest predictor of morbidity and mortality), the current cost burden of COPD in Europe could be reduced by up to €21B annually.

After winning a SMEi-1 grant and receiving a Seal of Excellence certificate for our first SMEi-2 application, we intend to complete several actions which will bring the PulseHaler™ to the commercial market in this SMEi-2 project. The design of the device will be finalized incorporating features and functions identified in our successful SMEi-1 project. We will then prepare the PulseHaler™ for large scale manufacturing. We will test the PulseHaler™ in a clinical study of COPD patients across several sites, to gather additional efficacy and usability data identified by KOLs in SMEi-1 as important to support uptake of the product in the market. We will continue to develop our reimbursement strategy for initial markets, finalize distribution arrangements in those markets, obtain regulatory approval, and proceed to launch the PulseHaler™.

Respinova Ltd. is a 10 year old SME based in Israel with 7 employees. We have a seasoned management team with decades of combined medical device, business and leadership experience.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STOP-COPD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STOP-COPD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

Plasmanorg (2019)

Environmental-friendly organic chemical synthesis in plasma reactor

Read More